Ritlecitinib is a new treatment for severe hair loss in people 12 and older.
Baricitinib may not always prevent relapse in alopecia areata.
September 2023 in “Dermatology and Therapy” Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.
September 2023 in “Journal of The American Academy of Dermatology” Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
May 2011 in “Value in Health” CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
26 citations
,
June 2024 in “Frontiers in Immunology” SOCS1 and SOCS3 help control skin inflammation and are important for developing treatments for skin diseases.
9 citations
,
May 2023 in “Inflammation Research” New small molecule drugs show promise in treating complex skin diseases but need more safety research.
March 2024 in “Dermatology and therapy” AA patients with comorbid conditions face more severe hair loss and need specific treatments.
11 citations
,
January 2022 in “Journal der Deutschen Dermatologischen Gesellschaft” Alopecia areata is a chronic condition causing hair loss, with new treatments targeting the immune system showing promise.
July 2023 in “The Egyptian Journal of Hospital Medicine ” Alopecia areata is a hair loss condition caused by immune factors and can be treated with JAK inhibitors.
2 citations
,
November 2021 in “ACG Case Reports Journal” Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
1 citations
,
August 2023 in “JAMA Dermatology” Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
January 2023 in “The Egyptian Journal of Hospital Medicine” New treatments for sudden hair loss include oral medications and a special laser, both showing promise in hair regrowth.
5 citations
,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
January 2026 in “Journal of Dermatology Research and Therapy” Combination therapy effectively regrows hair and reduces severity in Black children with stubborn Alopecia Areata.
July 2025 in “Preprints.org” Specific miRNA profiles can help diagnose and treat alopecia areata.
December 2023 in “European journal of dermatology/EJD. European journal of dermatology” More effective treatments are needed for severe alopecia areata.
August 2025 in “American Journal of Dermatopathology” Accurate diagnosis and personalized treatment are crucial in dermatopathology.
7 citations
,
November 2023 in “JAAD Case Reports” Baricitinib helped regrow hair in patients with severe alopecia areata after other treatments failed.
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
June 2021 in “DOAJ (DOAJ: Directory of Open Access Journals)” JAK inhibitors show promise for treating alopecia areata but their effectiveness and safety are still debated.
February 2025 in “PubMed” Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.
June 2020 in “Dermatologic therapy” Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.
June 2024 in “Bőrgyógyászati és Venerológiai Szemle” New treatments for hair loss, like JAK inhibitors, PRP, anti-androgens, and minoxidil, offer better options.
701 citations
,
August 2014 in “Nature medicine” Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.